REPL

Healthcare Biotechnology

Replimune Group, Inc.

$13.07

-0.47 -3.48% today

Price History

Not enough data

Key Stats

Market Cap

1.23B

Avg Volume

4.18M

EPS

-$3.15

52W High

$16.33

52W Low

$1.50

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-6.41

P/B Ratio

10.39

EV/EBITDA

-3.95

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(134.3%)

Return on Assets

(51.3%)

Liquidity & Leverage

Current Ratio

5.23

Quick Ratio

5.08

Debt / Equity

1.06

Total Cash

195.33M

Total Debt

111.97M

About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.